$SVSN CannaVision Announces February 1 Grand Opening of Their Bay Pines Medical Cannabis & Holistic Pain Management Clinic in St. Petersburg, Florida

Las Vegas, Nevada, Jan. 17, 2018 (GLOBE NEWSWIRE) — StereoVision Entertainment, Inc. (OTC PINK: SVSN), a publicly traded Nevada company, announces the February 1, 2018 Grand Opening of their majority owned subsidiary CannaVision’s Bay Pines medical cannabis and holistic pain management clinic at 9609 Bay Pines Blvd St Petersburg, Florida 33708. Calls for appointments are now being taken at 727-256-3452.

“While working closely with veterans’ organizations and advocating for veterans’ use of medical cannabis, our clinics are developing specific treatments designed to treat the approved conditions with medical cannabis products instead of opioids and other dangerous pharmaceuticals,” said CannaVision’s Chief Operating Officer Steven Previch. “We’re conducting studies as to the efficacy and possible side effects of medical cannabis treatments enabling us to establish the proper protocols and targeted treatment programs for all qualifying conditions. Our medical cannabis doctors can recommend the medical cannabis treatments to those patients that qualify, then they take our recommendations to licensed medical cannabis dispensaries, or online dispensaries, and they will deliver the medical cannabis directly to the patient. In Florida, certified medical marijuana doctors’ recommendations, which we provide at all CannaVision Clinics, are required to receive medical marijuana. While abiding by all state and federal laws, CannaVision Clinics provide the medical cannabis industry with an indispensable link in the chain.”

StereoVision Entertainment http://stereovision.comHeadquartered in Las Vegas, Nevada, StereoVision is a publicly traded Nevada corporation (OTC:SVSN) focused on creating, acquiring, and producing multimedia content with its media subsidiaries, the wholly owned 9 time Emmy Award winning production company REZN8, http://rezn8.com, the majority owned family entertainment company, Inspirational Vision Media, http://ivmi.biz, and the majority owned Florida medical marijuana clinic and organic/industrial hemp corporation MediCannaVision Inc., dba CannaVision. http://cannavisionclinics.com

Safe Harbor Statement: Except for historical information certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and those statements are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company cautions that these forward-looking statements are qualified by other factors. The Company undertakes no obligation to publicly update any statements in this release, whether as a result of future events, or otherwise.

Contact: Steven Previch 813-382-3569 Steven

Source: Stereo Vision Entertainment Inc

 © 2018 GlobeNewswire, Inc.

ESCRqueen The Court has scheduled a status update hearing for the Debtor on January 11, 2018.

"During the period from November 1st through November 30th, there were no material unusual or non-recurring accounting transactions recorded in the accompanying financial statements.

The Debtor continues to pursue a joint sale of its Atlantic Rim coalbed methane properties, along with Warren Resources, Inc., and will file any related sale documents with the Court accordingly.

The Court has scheduled a status update hearing for the Debtor on January 11, 2018.

Other significant events after the close of the reporting period:

In December 2017, the Debtor executed purchase and sales agreements with third-parties for the sale of its North Dakota/Montana (Bakken) properties and the sale of an oil well in Wyoming. The Debtor subsequently filed sales motions with the Court. The Debtor expects to close on the sales of these properties shortly after the Court issues an order granting these sales motions."


ESCRQ Security Details Other Company Securities
Share Structure
Market Value1 $67,245 a/o Jan 02, 2018
Authorized Shares 50,000,000 a/o Dec 28, 2017
Outstanding Shares 14,307,414 a/o Dec 28, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC 12,319,835 a/o Dec 28, 2017
Float Not Available
Par Value 0.1
Transfer Agent(s) Verified by Transfer Agent
Shareholders of Record 993 a/o Mar 12, 2009
Security Notes
New Issue=5-72 4,500,000 shs at 10 Cents by United Securities Corp.
Par Changed=2-27-84 1 cent to 10 cents Basis: 1 for 10 reverse split
Capital Change=8-84 shs increased by 100% stk div.
Note = Delisted from Nasdaq on 10-29-2015
Short Selling Data
Short Interest 172 (0%)
Dec 15, 2017
Significant Failures to Deliver No

ESCRQ Escalera Resources Co.
Common Stock SEC Reporting
0.00320.0015 (31.91%)

Real-Time Best Bid & Ask
0.0031 / 0.007 (1 x 1)
Previous Close
Daily Range
0.0032 – 0.0032
52wk Range
0.0027 – 0.055
Average Vol (30d)
Net Dividend Yield
Trade Data Delayed 15 minutes. Trade Time 11:44:00 ET / Last Best Bid & Ask Update Jan 3, 2018 11:44 AM ET

#DonaldTrump news $SPY collapsed! $VIX $AAPL $NFLX $TSLA

Wow! The market must be in a fragile state for the $SPY to have dropped 1% within 30 minutes of trading on news about Donald Trump and Michael Flynn. It’s as if the market isn’t going to require much negative news to start putting the brakes on this 2017 bull run.

By Ryan Vlastelica Dec. 1, 2017, 11:23 a.m. EST U.S. stocks fell sharply on Friday, turning lower in midday trading following reports that Michael Flynn will testify about President Donald Trump. The Dow Jones Industrial Average fell 162 points, or 0.7%, to 24,116. The S&P 500 lost 18 points to 2,630, a drop of 0.6 https://www.marketwatch.com/story/us-stocks-turn-lower-following-reports-flynn-will-testify-about-trump-2017-12-01

$ILIU Orig3n™ Acquires Interleukin Genetics, a Genetics-Based Personalized Health Company, to Advance the Futu re of Health Faster


Orig3n™ Acquires Interleukin Genetics, a Genetics-Based Personalized Health Company, to Advance the Future of Health Faster
Published: Nov 22, 2017 3:02 p.m. ET

The addition will support the accelerated growth of Orig3n’s direct-to-consumer genetic assessment business

BOSTON, Nov. 22, 2017 /PRNewswire/ — Orig3n, Inc., a Boston-based biotech company pioneering the future of health through genetics and regenerative medicine research, today announced the acquisition of Interleukin Genetics CLIA laboratory and their remaining assets. Interleukin Genetics’ technology will become a core component of Orig3n’s DNA test business to empower more people to take charge of their health through genetic insights.

Interleukin Genetics brings exceptional and valuable assets to Orig3n, including a CLIA-Certified Genetics Laboratory in Waltham, Massachusetts. The automated genotyping lab is fully-licensed for testing in all 50 U.S. states and is capable of processing over one million samples per year. In addition to the company’s state-of-the-art technology and its HIPAA and HITECH compliance, Interleukin Genetics also brings its ILUSTRA™ Inflammation Management Program and its Inherent Health® genetic tests for nutritional needs, weight management, heart health, and bone health to Orig3n. All personalized genetic tests will be consolidated under the Orig3n brand.

"Once we met with Interleukin Genetics, we saw a natural alignment between the two organizations regarding our shared commitment to a future of personalized health," said Robin Y. Smith, CEO of Orig3n. "With our trajectory of accelerated growth, we couldn’t imagine a better fit for acquisition. We are very pleased to be welcoming Interleukin Genetics to Orig3n."

Orig3n’s regenerative medicine research lab will remain in Boston’s Innovation District and the genetic testing will be consolidated to Interleukin Genetics’ CLIA laboratory. Rene Oda, previously the Director of Technology at Interleukin Genetics will join Orig3n as the Director of Product Management and Dr. Lynn Doucette-Stamm, joins as Senior Vice President of Development and Clinical Operations.

"We are looking forward to using our skillsets with Orig3n’s to expand the array of direct-to-consumer DNA tests," said Dr. Lynn Doucette-Stamm. "We see innovative growth opportunities ahead and we’re very excited to be joining a company focused on furthering the common good and advancing the future of health through genetics and regenerative medicine research."

About ORIG3N, Inc.
Founded in 2014, ORIG3N exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we’re on a mission to accelerate the future of health. For more information, visit www.orig3n.com.

Orig3n’s Guiding Beliefs:

We believe people should have direct, affordable access to information about their genes and their health.
We believe that when people better understand the links between genes, health, and behavior, they can make educated, proactive choices about their future.
We believe people should be in control of how their genetic information is used.
We believe diagnosing and treating disease shouldn’t be a matter of trial and error.
About Interleukin Genetics, Inc.Interleukin Genetics, Inc. develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include our proprietary cardiovascular test to guide treatment of high risk patients; our proprietary ILUSTRA Inflammation Management Program; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/orig3n-acquires-interleukin-genetics-a-genetics-based-personalized-health-company-to-advance-the-future-of-health-faster-300561135.html

SOURCE Orig3n, Inc.

Copyright (C) 2017 PR Newswire. All rights reserved


$ACST massive breakout +144%, can I get my $1.32 long stocks back?

$ACST I was long from ~$1.32 avg in anticipation of a large move such as what we saw yesterday. However, I took my profits at $1.60 in pre-market, didn’t realize it was going to open near $3.00! The early pre-market price premiums are usually a good time to take profits, but today it was not. Maybe no more non-regular hour trades…?

Does $GBTC have SEC Suspension and Trading Halt RISK? #BTC #Bitcoin

Maybe SEC halts GBTC soon? They already settled once with the SEC a year ago.



Common Stock – Each GBTC share represents ownership of approximately 0.1 bitcoin
$4608 x 0.1 = $460.8

Is $GBTC trading ~2x above what it should be?


$LEXG Lithium Exploration Group Announces Buyout of Largest Debt Holder PHOENIX, August 4, 2017 PRNewswire/

August 4, 2017 – 12:12 PM EDT
Email Article
Font Down
Font Up
LEXG 0.0008 0.0001

Today 5d 1m 3m 1y 5y 10y

Lithium Exploration Group Announces Buyout of Largest Debt Holder
PHOENIX, August 4, 2017 /PRNewswire/ —

Lithium Exploration Group, Inc. (OTC-PINK: LEXG) today announced today that its largest Debt holder with over $2.3mm in Debt has been Bought Out by a New Investor Group. The New Investor Group believes in the long term viability of the White Top Oil Investment and that the reserves will be proved out by the new seismic data.

CEO Alex Walsh stated "The timing of the But Out was spurred on by the positive reinforcement of Meir report and the potential 30% upside above and beyond the initial reserves of the property!."

About Lithium Exploration Group

Lithium Exploration Group is a US-based exploration and development company focused on the acquisition and development potential of lithium brines and other precious metals that demonstrate high probability for near-term production. Currently the company is focused on its Western Canada lithium assets, testing its Ultrasonic Generator Technology and the acquisition of oil and gas related assets in Western Canada. Lithium Exploration Group is a fully reporting company traded on the OTC Markets under the symbol LEXG. Website: http://www.lithiumexplorationgroup.com.

Safe Harbor Statement

This news release contains "forward-looking statements". Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future testing of the ultrasonic technology.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of lithium prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Shanon Chilson

SOURCE Lithium Exploration Group Inc.

Source: PR Newswire (August 4, 2017 – 12:12 PM EDT)

News by QuoteMedia